LDLR and familial hyperaldosteronism: In this scenario, monoclonal antibodies inhibiting PCSK9 have shown a robust effect in FH patients presenting a residual LDLR activity, while ANGPTL3 inhibitors appear to be promising in patients carrying null LDLR mutations.